Inclusion Criteria:  Willing and able to give consent/assent Clinical diagnosis of epidermolysis bullosa Confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1. Age: 6 months of age and older at the time of informed consent/assent Women of childbearing age must be willing to use reliable birth control method throughout the treatment duration and for 3 months following the last treatment application  Exclusion Criteria:  Diseases or conditions that could interfere with the assessment of safety of the study treatment and compliance of the participant with study visits/procedures, as determined by the Investigator Pregnant or nursing women Active infection in the area that will undergo administration, that the Investigator believes will negatively impact the IP application Known allergy to any of the constituents of the product Concurrent skin transplant or mesh skin grafting; if the participant is currently having transplantation or grafting surgeries they must wait until the transplant has begun to heal and the graft has absorbed prior to initiating B-VEC therapy Participation in an interventional gene therapy clinical trial within the past three (3) months (not including B-VEC administration)